icatibant (firazyr) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Priority Review FDA

Active Ingredient History

  • Now
Icatibant (trade name Firazyr) is a synthetic peptidomimetic drug consisting of ten amino acids, and acts as an effective and specific antagonist of bradykinin B2 receptors. It has been approved in the EU for use in hereditary angioedema, and is under investigation for a number of other conditions in which bradykinin is thought to play a significant role. Icatibant currently has orphan drug status in the United States and FDA approved on August 25, 2011. Icatibant inhibits bradykinin from binding the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.   NCATS

  • SMILES: N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N2C[C@H](O)C[C@H]2C(=O)NCC(=O)N[C@@H](Cc3cccs3)C(=O)N[C@@H](CO)C(=O)N4Cc5ccccc5C[C@@H]4C(=O)N6[C@H]7CCCC[C@H]7C[C@H]6C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
  • Mol. Mass: 1304.55
  • ALogP: Missing data
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)



United States

$971.5233 - $7466.8267
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

d-arg(hyp(3)-thi(5)-d-tic(7)-oic(8))bk | firazyr | hoe140 | hoe 140 | hoe-140 | hoechst 140 | hoechst-140 | icatibant | icatibant acetate | je 049 | je-049 | win 65365 | win-65365


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue